Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atazanavir
Drug ID BADD_D00176
Description Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Indications and Usage Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
Marketing Status Prescription; Discontinued
ATC Code J05AE08
DrugBank ID DB01072
KEGG ID D07471
MeSH ID D000069446
PubChem ID 148192
TTD Drug ID D07IQS
NDC Product Code 42385-921; 65862-713; 0003-3631; 70518-1365; 70710-1052; 70771-1591; 65862-710; 69097-443; 0003-3622; 69097-444; 65862-711; 11014-0175; 69097-446; 70771-1592; 69238-1137; 16714-860; 31722-654; 42385-922; 42385-920; 0003-3638; 70771-1593; 70710-1051; 0003-3624; 31722-653; 65862-712; 69097-445; 31722-655; 69238-1136; 16714-861; 69238-1138; 70710-1050; 69238-1135; 16714-862; 70518-2832; 0904-6875
Synonyms Atazanavir Sulfate | Reyataz | Atazanavir | 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester | CGP 75176 | CGP75176 | CGP-75176 | CGP 73547 | CGP-73547 | CGP73547 | CGP 75355 | CGP75355 | CGP-75355 | CGP 75136 | CGP75136 | CGP-75136 | BMS-232632-05 | BMS 232632 05 | BMS23263205 | BMS 232632 | 232632, BMS | BMS-232632 | BMS232632
Chemical Information
Molecular Formula C38H52N6O7
CAS Registry Number 198904-31-3
SMILES CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)N C(=O)OC)O)NC(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hepatic pain09.01.05.0050.008268%
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis C09.01.09.005; 11.05.06.004--Not Available
Hepatitis viral11.05.04.011; 09.01.09.007--
Hepatocellular injury09.01.07.0080.011024%Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatosplenomegaly09.01.05.002; 01.09.03.001--Not Available
Hiccups22.02.04.002; 07.01.06.009--
Hostility19.05.01.003--Not Available
Hydronephrosis20.01.05.0010.005512%Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.027560%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.005512%
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperlactacidaemia14.01.01.006--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertriglyceridaemia14.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypothalamo-pituitary disorder05.03.04.0030.011024%Not Available
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages